ARTICLE | Management Tracks
Armstrong takes new role at Dana-Farber
Plus: The Carlyle Group’s Rubenstein to join Moderna’s board and updates from Geron, Vedanta, Vericel, Metrion and PharmaEssentia
July 23, 2024 11:15 PM UTC
Dana-Farber Cancer Institute named Scott Armstrong as SVP for drug discovery and chief research strategy officer. Armstrong is a professor at Harvard University and was an attending physician at the institute for 11 years until 2012.
The Carlyle Group’s David Rubenstein will join the board of Moderna Inc. (NASDAQ:MRNA) on Aug. 5 and succeed Stephen Berenson as a member of its audit committee. In addition to Berenson, co-founder Robert Langer is also retiring from Moderna’s board; a search for a replacement is ongoing. Rubenstein is chairman of the council on foreign relations and chairman of the Economic Club of Washington, D.C...